Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab + TCS in Japanese Patients with Moderate-to-Severe Atopic Dermatitis
NCT04760314Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Mar 2021; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04760314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04760314.